FDA Approves Johnson & Johnson’s TREMFYA for Pediatric Psoriasis and Psoriatic Arthritis
HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) announced that the U.S. Food and Drug Administration has approved TREMFYA® (guselkumab) for children six years and older weighing at least 40 …
FDA Approves Johnson & Johnson’s TREMFYA for Pediatric Psoriasis and Psoriatic Arthritis Read More